NCT02693652 is a Phase 1, PHASE2 clinical trial of CVI-HBV-002 in Hepatitis B, Chronic, sponsored by CHA Vaccine Institute Co., Ltd..

Who is sponsoring NCT02693652?

NCT02693652 is sponsored by CHA Vaccine Institute Co., Ltd..

What drugs are being tested in NCT02693652?

Interventions in NCT02693652: CVI-HBV-002.

What condition does NCT02693652 study?

NCT02693652 studies Hepatitis B, Chronic.

Is NCT02693652 still recruiting?

NCT02693652 is currently completed. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT02693652

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine

Completed Phase 1, PHASE2 Last updated 18 November 2023

What this trial tests

Phase 1, PHASE2 trial testing CVI-HBV-002 in Hepatitis B, Chronic in 53 participants. Completed in 22 August 2017.

Timeline

28 October 2014

Primary endpoint
22 August 2017

22 August 2017

Quick facts

Lead sponsor	CHA Vaccine Institute Co., Ltd.
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	53
Start date	28 October 2014
Primary completion	22 August 2017
Estimated completion	22 August 2017
Sites	1 location across South Korea

Drugs / interventions tested

CVI-HBV-002 — full drug profile →

Conditions studied

Hepatitis B, Chronic — all drugs for Hepatitis B, Chronic →

Sponsor

CHA Vaccine Institute Co., Ltd. — full company profile →

Who can join

Adults 19 to 60, any sex, with Hepatitis B, Chronic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A single center, open labeled phase I/IIa study to evaluate safety, tolerability and efficacy of a therapeutic hepatitis B vaccine in oral antiviral drug-treated chronic hepatitis B virus carriers

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications.
Boni C, Barili V, Acerbi G, Rossi M, et al · · 2019 · cited 42× · PMID 31195619 · DOI 10.3390/ijms20112754
Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS, Kim DS, Kim JH, Heo Y, et al · · 2022 · cited 29× · PMID 35764365 · DOI 10.1136/jitc-2022-004799
The significance of antibody to hepatitis B surface antigen in infection and clearance of hepatitis B virus.
Ding L, Huang J, Huang S. · · 2025 · cited 3× · PMID 39754388 · DOI 10.1080/21645515.2024.2445283
Research and Development of Hepatitis B Drugs: An Analysis Based on Technology Flows Measured by Patent Citations.
Huang C, Lin HH, Wan JB, He C, et al · · 2016 · cited 2× · PMID 27727319 · DOI 10.1371/journal.pone.0164328

Verify or expand the search:

Other trials of CVI-HBV-002

Trials testing the same drug.

NCT06147895 — A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Prophylactic Hepatitis B Vaccine · Phase 1 · completed
NCT04289987 — A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine · Phase 2 · completed

Other recruiting trials for Hepatitis B, Chronic

Currently open trials in the same condition.

NCT07370207 — Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region · Phase 2 · recruiting
NCT06550622 — Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion · recruiting
NCT06550128 — Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB). · Phase 2 · active not recruiting
NCT06525909 — A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B · recruiting
NCT05937178 — Real-world Study Optimizing Nucleotide-analogues · recruiting

Other CHA Vaccine Institute Co., Ltd. trials

Trials by the same sponsor.

NCT06137755 — Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above · Phase 1 · recruiting
NCT06147895 — A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Prophylactic Hepatitis B Vaccine · Phase 1 · completed
NCT04289987 — A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine · Phase 2 · completed
NCT02692170 — A Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of the Third Generation Hepatitis B Vaccine · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02693652 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CHA Vaccine Institute Co., Ltd.
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02693652.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing